The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.
- Biofluids may include blood, cerebrospinal fluid, saliva and tears.
- Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered.
- Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability.
Watch a previously recorded webinar on our Foundation's funding strategy and opportunities, and the application and review processes